Talk:Adenosine monophosphate deaminase deficiency type 1
Medicine Start‑class Mid‑importance | ||||||||||
|
Requested move
It has been proposed in this section that Adenosine monophosphate deaminase deficiency type 1 be renamed and moved to Adenosine Monophosphate Deaminase Deficiency type 1 (AMPD1). A bot will list this discussion on requested moves' current discussions subpage within an hour of this tag being placed. The discussion may be closed 7 days after being opened, if consensus has been reached (see the closing instructions). Please base arguments on article title policy, and keep discussion succinct and civil. Please use {{subst:requested move}} . Do not use {{requested move/dated}} directly. |
Myoadenylate deaminase deficiency → Adenosine Monophosphate Deaminase Deficiency type 1 (AMPD1) –
The primary name for Myoadenlylate Deaminase Deficiency (MAD or MADD) has been changed in the last decade, as referenced below by: Orphanet (Rare Disease Research) - 36 countries are members. US National Institutes of Health (NIH).
See the following references.
[1]
[2]
Cite error: A <ref>
tag is missing the closing </ref>
(see the help page).
67.189.56.3 (talk) 02:59, 15 August 2011 (UTC)Tom
- ^ {cite web |url=http://ghr.nlm.nih.gov/gene/AMPD1 |title=AMPD1 Gene]]
- ^ {cite web |url=http://ghr.nlm.nih.gov/condition/adenosine-monophosphate-deaminase-deficiency |title=Adenosine monophosphate deaminase deficiency}}